Drug Profile
Research programme: antisense therapies - Ercole/Isis
Latest Information Update: 02 Jul 2009
Price :
$50
*
At a glance
- Originator Ercole Biotech; Isis Pharmaceuticals
- Class Antisense elements
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer; Cardiovascular disorders; Prostate cancer; Psoriasis
Most Recent Events
- 26 May 2003 Preclinical trials in Breast cancer in USA (unspecified route)
- 26 May 2003 Preclinical trials in Cardiovascular disorders in USA (unspecified route)
- 26 May 2003 Preclinical trials in Prostate cancer in USA (unspecified route)